{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:13:40Z","timestamp":1790255620661,"version":"4.1.0"},"reference-count":66,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In this response-adapted clinic trial with daratumumab monotherapy for older patients with newly diagnosed multiple myeloma (MM), we identified target antigen expression, a plasma cell phenotype, and an activated immune tumor microenvironment (iTME) as critical features associated with response to CD38 monoclonal antibody therapy. Here, patients achieving a partial response after 2 cycles continued daratumumab, otherwise lenalidomide or bortezomib was added. This strategy resulted in an overall response rate of 97% and low rates of adverse events, with 37% of patients able to continue daratumumab monotherapy. Importantly, we found that higher CD38 expression, plasma cell gene expression programming, and an activated iTME were associated with patients who were able to continue daratumumab therapy alone. In contrast, patients requiring the addition of lenalidomide or bortezomib had increased expression of adhesion, tumor necrosis factor signaling, KRAS signaling, and B-cell programs, as well as an immunosuppressed iTME. Tracking of clonal dynamics illustrated the selection of subclones enriched for de novo resistance gene expression programs after only 2 cycles of daratumumab monotherapy. Upon relapse, daratumumab refractory MM cells were characterized by the expansion of preexisting minor subclones with mixed transcriptomic programs containing the plasma cell phenotype with decreased CD38 expression and maintenance of resistance programs, suggesting development of acquired resistance involves an uncoupling of transcriptional programs present in therapy-na\u00efve tumors. To our knowledge, this is the first study to demonstrate the effectiveness of response-adapted daratumumab treatment and describe critical biomarkers of single-agent daratumumab sensitivity in vulnerable patients with therapy-na\u00efve MM. This trial was registered at www.ClinicalTrials.gov as #NCT04151667.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029921","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:53:47Z","timestamp":1758578027000},"page":"497-512","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0259-1875","authenticated-orcid":false,"given":"Mark B.","family":"Meads","sequence":"first","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Noyes","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1283-9332","authenticated-orcid":false,"given":"Praneeth R.","family":"Sudalagunta","sequence":"additional","affiliation":[{"name":"2Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Achille","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaomei","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-8512","authenticated-orcid":false,"given":"Rafael R.","family":"Canevarolo","sequence":"additional","affiliation":[{"name":"2Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Silva","sequence":"additional","affiliation":[{"name":"2Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Magaletti","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5421-3425","authenticated-orcid":false,"given":"Daniel","family":"DeAvila","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonila","family":"Toska","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Oates","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lastorino","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6115-3348","authenticated-orcid":false,"given":"Dietrich Werner","family":"Idiaquez","sequence":"additional","affiliation":[{"name":"4Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Song","sequence":"additional","affiliation":[{"name":"4Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-7149","authenticated-orcid":false,"given":"Samer S.","family":"Sansil","sequence":"additional","affiliation":[{"name":"5Cancer Pharmacokinetics and Pharmacodynamics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Yoder","sequence":"additional","affiliation":[{"name":"3Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel F.","family":"Grajales-Cruz","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Blue","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"7Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-2226","authenticated-orcid":false,"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"7Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Brayer","sequence":"additional","affiliation":[{"name":"8Departments of Malignant Hematology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariosto S.","family":"Silva","sequence":"additional","affiliation":[{"name":"2Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Song","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8888","authenticated-orcid":false,"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-4733","authenticated-orcid":false,"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10068","key":"2026012911212700500_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"2026012911212700500_bib2","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"2026012911212700500_bib3","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"10027","key":"2026012911212700500_bib4","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"2026012911212700500_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.15700","article-title":"Lenalidomide-based response-adapted therapy for older adults without high risk myeloma","volume":"184","author":"Baz","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2026012911212700500_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"issue":"45","key":"2026012911212700500_bib7","doi-asserted-by":"crossref","first-page":"18342","DOI":"10.1073\/pnas.1106550108","article-title":"CD47-signal regulatory protein-\u03b1 (SIRP\u03b1) interactions form a barrier for antibody-mediated tumor cell destruction","volume":"108","author":"Zhao","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"2026012911212700500_bib8","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Perez de Acha","year":"2023","journal-title":"Blood Adv"},{"issue":"25","key":"2026012911212700500_bib9","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.2024026455","article-title":"The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy","volume":"145","author":"Korst","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026012911212700500_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-024-01096-6","article-title":"Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma","volume":"14","author":"Ziccheddu","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026012911212700500_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"2026012911212700500_bib12","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens","volume":"4","author":"Maura","year":"2023","journal-title":"Nat Cancer"},{"issue":"2","key":"2026012911212700500_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/0008-5472.CAN-24-0886","article-title":"The functional transcriptomic landscape informs therapeutic strategies in multiple myeloma","volume":"85","author":"Sudalagunta","year":"2025","journal-title":"Cancer Res"},{"issue":"12","key":"2026012911212700500_bib14","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-17-0502","article-title":"An ex vivo platform for the prediction of clinical response in multiple myeloma","volume":"77","author":"Silva","year":"2017","journal-title":"Cancer Res"},{"issue":"3","key":"2026012911212700500_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1040-8428(00)00089-5","article-title":"The application of the principles of geriatrics to the management of the older person with cancer","volume":"35","author":"Balducci","year":"2000","journal-title":"Crit Rev Oncol Hematol"},{"issue":"23","key":"2026012911212700500_bib16","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/0008-5472.CAN-22-2350","article-title":"CK1\u03b4 and CK1\u03b5 signaling sustains mitochondrial metabolism and cell survival in multiple myeloma","volume":"83","author":"Burger","year":"2023","journal-title":"Cancer Res"},{"key":"2026012911212700500_bib30","author":"Tickle","year":"2019"},{"issue":"7965","key":"2026012911212700500_bib17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","article-title":"Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours","volume":"618","author":"Gavish","year":"2023","journal-title":"Nature"},{"key":"2026012911212700500_bib18","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"2026012911212700500_bib19","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41423-020-00574-8","article-title":"Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia","volume":"18","author":"Crinier","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"2026012911212700500_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.immuni.2019.01.001","article-title":"Single-cell transcriptomics of regulatory T cells reveals trajectories of tissue adaptation","volume":"50","author":"Miragaia","year":"2019","journal-title":"Immunity"},{"issue":"8","key":"2026012911212700500_bib21","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","article-title":"Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease","volume":"54","author":"Mulder","year":"2021","journal-title":"Immunity"},{"issue":"24","key":"2026012911212700500_bib22","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1818488116","article-title":"Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRV\u03b41 and TCRV\u03b42 \u03b3\u03b4 T lymphocytes","volume":"116","author":"Pizzolato","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6335","key":"2026012911212700500_bib23","doi-asserted-by":"crossref","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"issue":"6","key":"2026012911212700500_bib24","doi-asserted-by":"crossref","first-page":"e105123","DOI":"10.15252\/embj.2020105123","article-title":"Mapping the origin and fate of myeloid cells in distinct compartments of the eye by single-cell profiling","volume":"40","author":"Wieghofer","year":"2021","journal-title":"EMBO J"},{"issue":"7","key":"2026012911212700500_bib25","doi-asserted-by":"crossref","first-page":"e147719","DOI":"10.1172\/JCI147719","article-title":"Single-cell RNA sequencing reveals induction of distinct trained-immunity programs in human monocytes","volume":"132","author":"Zhang","year":"2022","journal-title":"J Clin Invest"},{"issue":"6574","key":"2026012911212700500_bib26","doi-asserted-by":"crossref","first-page":"abe6474","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"issue":"10","key":"2026012911212700500_bib27","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/cyto.a.23598","article-title":"OMIP-049: analysis of human myelopoiesis and myeloid neoplasms","volume":"93","author":"Zhu","year":"2018","journal-title":"Cytometry A"},{"issue":"8","key":"2026012911212700500_bib28","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"2026012911212700500_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2307\/2531294","article-title":"Confidence limits for probability of response in multistage phase II clinical trials","volume":"41","author":"Atkinson","year":"1985","journal-title":"Biometrics"},{"issue":"3","key":"2026012911212700500_bib31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-20-2246","article-title":"Exploiting protein translation dependence in multiple myeloma with omacetaxine-based therapy","volume":"27","author":"Walker","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026012911212700500_bib32","doi-asserted-by":"crossref","first-page":"e2304020121","DOI":"10.1073\/pnas.2304020121","article-title":"Targeted checkpoint control of B cells undergoing positive selection in germinal centers by follicular regulatory T cells","volume":"121","author":"Ke","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2026012911212700500_bib33","doi-asserted-by":"crossref","first-page":"e2021342118","DOI":"10.1073\/pnas.2021342118","article-title":"CD20 as a gatekeeper of the resting state of human B cells","volume":"118","author":"Kl\u00e4sener","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"2026012911212700500_bib34","doi-asserted-by":"crossref","first-page":"e2205629119","DOI":"10.1073\/pnas.2205629119","article-title":"LAPTM5 mediates immature B cell apoptosis and B cell tolerance by regulating the WWP2-PTEN-AKT pathway","volume":"119","author":"Wang","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026012911212700500_bib35","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1172\/JCI129025","article-title":"Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance","volume":"129","author":"Nambiar","year":"2019","journal-title":"J Clin Invest"},{"issue":"4","key":"2026012911212700500_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41590-021-00889-2","article-title":"Wnt-beta-catenin activation epigenetically reprograms T(reg) cells in inflammatory bowel disease and dysplastic progression","volume":"22","author":"Quandt","year":"2021","journal-title":"Nat Immunol"},{"issue":"12","key":"2026012911212700500_bib37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41590-018-0236-6","article-title":"Activated beta-catenin in Foxp3(+) regulatory T cells links inflammatory environments to autoimmunity","volume":"19","author":"Sumida","year":"2018","journal-title":"Nat Immunol"},{"issue":"6282","key":"2026012911212700500_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"issue":"4","key":"2026012911212700500_bib39","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaci.2022.04.011","article-title":"STAT5B restrains human B-cell differentiation to maintain humoral immune homeostasis","volume":"150","author":"Pelham","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2026012911212700500_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"2026012911212700500_bib41","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","article-title":"CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat Protoc"},{"key":"2026012911212700500_bib42","doi-asserted-by":"crossref","first-page":"110494","DOI":"10.1016\/j.intimp.2023.110494","article-title":"MIF promotes Th17 cell differentiation in Hashimoto's thyroiditis by binding HVEM and activating NF-\u03baB signaling pathway","volume":"121","author":"Liu","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2026012911212700500_bib43","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1038\/s41598-023-37779-6","article-title":"The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells","volume":"13","author":"Kaulfuss","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"2026012911212700500_bib44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"2026012911212700500_bib45","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/s41467-021-22359-x","article-title":"Structural plasticity of KIR2DL2 and KIR2DL3 enables altered docking geometries atop HLA-C","volume":"12","author":"Moradi","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"2026012911212700500_bib46","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2026012911212700500_bib47","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1172\/JCI130426","article-title":"IRF4 instructs effector Treg differentiation and immune suppression in human cancer","volume":"130","author":"Alvisi","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"2026012911212700500_bib48","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41467-021-22975-7","article-title":"Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation","volume":"12","author":"Mijnheer","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"2026012911212700500_bib49","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2026012911212700500_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1074-7613(03)00208-5","article-title":"Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6","volume":"19","author":"Jego","year":"2003","journal-title":"Immunity"},{"issue":"2","key":"2026012911212700500_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4049\/jimmunol.2200538","article-title":"Type I IFN receptor signaling on B cells promotes antibody responses to polysaccharide antigens","volume":"210","author":"Spurrier","year":"2023","journal-title":"J Immunol"},{"issue":"15","key":"2026012911212700500_bib52","doi-asserted-by":"crossref","first-page":"e110218","DOI":"10.15252\/embj.2021110218","article-title":"CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma","volume":"41","author":"Wang","year":"2022","journal-title":"EMBO J"},{"issue":"34","key":"2026012911212700500_bib53","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1038\/s41388-021-01932-0","article-title":"CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy","volume":"40","author":"Sun","year":"2021","journal-title":"Oncogene"},{"issue":"12","key":"2026012911212700500_bib54","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1136\/gutjnl-2022-329349","article-title":"CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-\u03baB\/p65 nuclear translocation in pancreatic ductal adenocarcinoma","volume":"72","author":"Liu","year":"2023","journal-title":"Gut"},{"key":"2026012911212700500_bib55","doi-asserted-by":"crossref","first-page":"104961","DOI":"10.1016\/j.ebiom.2023.104961","article-title":"CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy","volume":"100","author":"Tang","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"2026012911212700500_bib56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.immuni.2016.06.011","article-title":"Mitochondrial pyruvate import promotes long-term survival of antibody-secreting plasma cells","volume":"45","author":"Lam","year":"2016","journal-title":"Immunity"},{"issue":"7628","key":"2026012911212700500_bib57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature20123","article-title":"Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma","volume":"539","author":"Tirosh","year":"2016","journal-title":"Nature"},{"issue":"2","key":"2026012911212700500_bib58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2026012911212700500_bib66","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"issue":"4","key":"2026012911212700500_bib59","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"2026012911212700500_bib60","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"2026012911212700500_bib61","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s43018-023-00544-9","article-title":"Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma","volume":"4","author":"Kropivsek","year":"2023","journal-title":"Nat Cancer"},{"issue":"3","key":"2026012911212700500_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"issue":"9","key":"2026012911212700500_bib63","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"issue":"2","key":"2026012911212700500_bib64","doi-asserted-by":"crossref","first-page":"890","DOI":"10.4049\/jimmunol.182.2.890","article-title":"Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells","volume":"182","author":"Good","year":"2009","journal-title":"J Immunol"},{"issue":"3","key":"2026012911212700500_bib65","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/cmi.2013.2","article-title":"Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy","volume":"10","author":"Pedroza-Pacheco","year":"2013","journal-title":"Cell Mol Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025029921\/2501371\/blood_bld-2025-029921-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025029921\/2501371\/blood_bld-2025-029921-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:21:42Z","timestamp":1769703702000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/5\/497\/547403\/Target-antigen-and-plasma-cell-phenotype-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029921","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,29]]},"published":{"date-parts":[[2026,1,29]]}}}